UNITY Biotechnology Inc
NASDAQ:UBX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
UNITY Biotechnology Inc
Other Items
UNITY Biotechnology Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
UNITY Biotechnology Inc
NASDAQ:UBX
|
Other Items
$22.5m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Items
-$5.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
32%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Items
-$4.2B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
21%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Items
-$85m
|
CAGR 3-Years
74%
|
CAGR 5-Years
55%
|
CAGR 10-Years
33%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Items
-$507.8m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Items
$584.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
UNITY Biotechnology Inc
Glance View
Unity Biotechnology, Inc. operates as a biotechnology company. The company is headquartered in Brisbane California, California and currently employs 65 full-time employees. The company went IPO on 2018-05-03. The firm is engaged in developing a portfolio of programs targeting specific biological mechanisms implicated in diseases of aging. The firm is focused on creating senolytic medicines to selectively eliminate senescent cells and thereby treat diseases of aging, such as ophthalmologic diseases, with the opportunity to explore neurology and other therapeutic areas. The firm's product includes UBX1325, UBX2089 and UBX2050. UBX1325 is an advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR). UBX2089, an α-Klotho hormone drug candidate, is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications. UBX2050 is investigating fully human anti-Tie2 agonist monoclonal antibody.
See Also
What is UNITY Biotechnology Inc's Other Items?
Other Items
22.5m
USD
Based on the financial report for Mar 31, 2025, UNITY Biotechnology Inc's Other Items amounts to 22.5m USD.
What is UNITY Biotechnology Inc's Other Items growth rate?
Other Items CAGR 5Y
-7%
Over the last year, the Other Items growth was -30%. The average annual Other Items growth rates for UNITY Biotechnology Inc have been 5% over the past three years , -7% over the past five years .
